TGTX — TG Therapeutics, Inc.
$64.51
$-0.05 (-0.08%)
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Market Cap
$9.75B
Forward P/E
24.4x
52-Week Range
N/A
TGTX Price History
Revenue vs. Net Income
$616M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$25M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
14.7%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
2.6x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.0%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+0.7%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
